Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes supportive care products. The Company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients. Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The Company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes, and other product candidates, including other dronabinol line extensions and sublingual spray product candidates.

Employee Rating

2.1More
TypePublic
HQChandler, US
Founded1998
Size (employees)423 (est)
Websiteinsysrx.com
Insys Therapeutics was founded in 1998 and is headquartered in Chandler, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Insys Therapeutics

Saeed Motahari

Saeed Motahari

President and CEO
Andrew Long

Andrew Long

CFO
Franc Del Fosse

Franc Del Fosse

General Counsel
Sanga Emmanuel

Sanga Emmanuel

VP, Chief Compliance Officer
Venkat Goskonda

Venkat Goskonda

Senior VP, Research & Development
Daniel Pon

Daniel Pon

VP, Human Resources
Show more

Insys Therapeutics Office Locations

Insys Therapeutics has offices in Chandler and Round Rock
Chandler, US (HQ)
1333 S Spectrum Blvd #100
Chandler, US
444 S Ellis St and 410 S Benson Ln
Round Rock, US
2700 Oakmont Drive
Show all (3)
Report incorrect company information

Insys Therapeutics Financials and Metrics

Insys Therapeutics Revenue

Insys Therapeutics's revenue was reported to be $140.69 m in FY, 2017
USD

Revenue (Q3, 2018)

18.3m

Gross profit (Q3, 2018)

16.0m

Gross profit margin (Q3, 2018), %

87%

Net income (Q3, 2018)

(30.5m)

EBIT (Q3, 2018)

(30.8m)

Market capitalization (16-Jan-2019)

320.1m

Closing stock price (16-Jan-2019)

4.3

Cash (30-Sep-2018)

20.8m
Insys Therapeutics's current market capitalization is $320.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

99.3m222.1m330.8m242.3m140.7m

Revenue growth, %

124%49%(27%)

Cost of goods sold

12.7m28.9m25.4m20.6m

Gross profit

86.6m301.9m216.9m120.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

29.2m41.6m55.7m58.3m70.8m77.6m91.3m62.0m67.1m55.2m36.0m42.6m30.7m23.9m23.5m18.3m

Cost of goods sold

3.1m4.8m6.6m5.4m6.4m8.3m7.7m4.6m6.3m4.7m4.6m3.9m7.5m2.2m3.6m2.4m

Gross profit

26.1m36.9m49.1m52.9m64.4m69.3m83.6m57.3m60.8m50.5m31.3m38.7m23.2m21.7m19.9m16.0m

Gross profit Margin, %

89%89%88%91%91%89%92%93%91%92%87%91%76%91%85%87%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

45.4m58.1m79.5m104.6m32.0m

Accounts Receivable

Inventories

14.5m34.8m41.7m21.7m17.4m

Current Assets

82.2m151.0m253.2m231.0m175.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

31.3m40.0m46.1m47.4m70.1m74.0m94.0m73.8m69.3m93.5m68.4m49.8m35.8m18.5m16.1m20.8m

Accounts Receivable

12.4m19.1m

Inventories

11.7m19.4m24.7m31.4m35.2m35.6m39.4m32.2m29.2m28.0m21.3m20.0m18.4m16.3m10.0m10.8m

Current Assets

57.7m91.3m102.2m128.7m182.1m198.2m236.6m220.8m234.0m235.2m196.9m197.2m179.9m166.7m156.1m145.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

40.4m58.5m7.6m(228.0m)

Depreciation and Amortization

1.8m2.5m5.3m6.2m7.3m

Inventories

(7.4m)(20.0m)(6.9m)15.0m2.3m

Accounts Payable

Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

16.3m7.7m17.1m28.6m8.0m15.3m41.5m2.4m6.8m7.0m(6.5m)(14.7m)(181.0m)(20.4m)(47.7m)(78.2m)

Depreciation and Amortization

1.3m523.0k1.1m1.7m2.5m3.8m1.5m3.0m4.5m1.8m3.7m5.5m1.9m3.8m5.7m

Inventories

(4.7m)(4.9m)(10.2m)(16.9m)35.2m(772.0k)(4.6m)9.5m2.4m6.3m1.7m345.0k705.0k1.0m930.0k753.0k

Accounts Payable

15.1m24.5m36.6m30.6m24.2m25.7m22.2m17.5m28.2m
USDY, 2018

Financial Leverage

1.6 k x
Show all financial metrics
Report incorrect company information

Insys Therapeutics News and Updates

Global Medical Cannabis Market Growth Forecast Up to 2025 Analysis By Companies like BOL Pharma, Tilray, Medreleaf Corporation, Aurora Cannabis, Canopy Growth Corporation, Insys Therapeutics, Inc., Medical Marijuana Inc.

Summary This report includes market status and forecast of global and major regions, with the introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Posted via Industry Today. Follow us on Twitter @Indu…

Johnson Fistel Announces Investigations of Veevo Instruments Inc., Insys Therapeutics, Inc., TAL Education Group and Newell Brands Inc.; Investors Encouraged to Contact Firm

SAN DIEGO, June 23, 2018 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Veevo Instruments Inc., Insys Therapeutics, Inc., TAL Education Group and Newell Brands Inc., as detailed below: Veevo Instruments Inc.(VECO) Johnson...
Report incorrect company information

Insys Therapeutics Blogs

INSYS Therapeutics Provides Update on Strategic Alterative Review Process and Product Pipeline Spanning Pharmaceutical Cannabinoids and Spray Technology

Transformational momentum building as Company plans to apply for two NDAs in 2019 PHOENIX , Dec. 17, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today provided

INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy

INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy Content Import Tue, 12/04/2018 - 06:02 INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Ep…

Clinical Data from Long-Term Safety Study of Company’s Pharmaceutical CBD in Refractory Pediatric Epilepsy To Be Presented at American Epilepsy Society Meeting

Clinical Data from Long-Term Safety Study of Company’s Pharmaceutical CBD in Refractory Pediatric Epilepsy To Be Presented at American Epilepsy Society Meeting ma.celeste.loy… Tue, 11/20/2018 - 07:02 Clinical Data from Long-Term Safety Study of Company’s Pharmaceutical CBD in Refractory Pe…

Elizabeth Bohlen

Elizabeth Bohlen ma.celeste.loy… Wed, 10/03/2018 - 13:45 Member of the Compliance Committee Member of the Nominating and Corporate Governance Committee Elizabeth Bohlen Directors

INSYS Therapeutics Signs Definitive License Agreement with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East

PHOENIX , Oct. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that it has signed a definitive license agreement with Lunatus for

Insys Therapeutics Company Life and Culture

Report incorrect company information

Insys Therapeutics Frequently Asked Questions

  • When was Insys Therapeutics founded?

    Insys Therapeutics was founded in 1998.

  • Who are Insys Therapeutics key executives?

    Insys Therapeutics's key executives are Saeed Motahari, Andrew Long and Franc Del Fosse.

  • How many employees does Insys Therapeutics have?

    Insys Therapeutics has 423 employees.

  • What is Insys Therapeutics revenue?

    Latest Insys Therapeutics annual revenue is $140.7 m.

  • What is Insys Therapeutics revenue per employee?

    Latest Insys Therapeutics revenue per employee is $332.6 k.

  • Who are Insys Therapeutics competitors?

    Competitors of Insys Therapeutics include Assertio Therapeutics, Apollomics and Delcath Systems.

  • Where is Insys Therapeutics headquarters?

    Insys Therapeutics headquarters is located at 1333 S Spectrum Blvd #100, Chandler.

  • Where are Insys Therapeutics offices?

    Insys Therapeutics has offices in Chandler and Round Rock.

  • How many offices does Insys Therapeutics have?

    Insys Therapeutics has 3 offices.